Clinical Gastroenterology and Hepatology
Volume 6, Issue 11 , Pages 1255-1262, November 2008

Elevated Soluble Tumor Necrosis Factor Receptor 75 Concentrations Identify Patients With Liver Cirrhosis at Risk of Death

  • Frank Grünhage

      Affiliations

    • Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany
  • ,
  • Bettina Rezori

      Affiliations

    • Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany
  • ,
  • Markus Neef

      Affiliations

    • Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany
  • ,
  • Frank Lammert

      Affiliations

    • Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany
  • ,
  • Tilman Sauerbruch

      Affiliations

    • Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany
  • ,
  • Ulrich Spengler

      Affiliations

    • Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany
  • ,
  • Christoph Reichel

      Affiliations

    • Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Bonn, Germany
    • Rehabilitation Center Bad Brückenau, Clinic Hartwald, German Pension Insurance, Federal Office, Bad Brückenau, Germany
    • Corresponding Author InformationAddress requests for reprints to: Priv-Doz Dr Christoph Reichel, Reha-Zentrum Bad Brückenau, Klinik Hartwald, Deutsche Rentenversicherung Bund, Schlüchterner Str. 4, 97769 Bad Brückenau, Germany. fax: 0049-9741-82-198

Background & Aims

Elevated levels of the soluble 75-kd receptor for tumor necrosis factor–alpha (sTNF-R 75) are better predictors of mortality in cirrhosis than the Child-Turcotte-Pugh (CTP) score. Thus, we compared sTNF-R 75 with the Model for End-Stage Liver Disease (MELD), CTP, and the sTNF-R 75/55 ratio.

Methods

Ninety-two patients with liver cirrhosis (mean age, 55 years; range, 19–76 years; male, 66%; CTP stage C, 41%) were included in our prospective single-center survival study. The study setting was a tertiary care university clinic. Soluble TNF-R levels were determined, and the primary end point was death.

Results

During ≥730 days, 44 patients died. Multivariate Cox regression analysis revealed sTNF-R 75 (≥14 ng/mL) as an independent predictor of mortality (hazard ratio, 2.53; P = .006). By receiver operating characteristic, MELD and sTNF-R 75 were more accurate in predicting 6-, 15-, and 24-month mortality than CTP and sTNF-R 75/55. This was significant for 6 months (MELD, 0.78; sTNF-R 75, 0.75 vs sTNF-R 75/55, 0.60). In patients with high MELD scores (≥15), survival was further reduced if sTNF-R 75 values were elevated (P = .035).

Conclusions

Elevated sTNF-R 75 levels independently predicted mortality and improved MELD on the basis of evaluation of prognosis, especially in patients with high MELD scores. Thus, sTNF-R 75 levels might be a useful cytokine-based prognostic marker in patients with liver cirrhosis.

Abbreviations used in this paper: AUC, area under the curve, CI, confidence interval, CTP, Child-Turcotte-Pugh, CV, coefficient of variation, INR, international normalized ratio, MELD, Model for End-Stage Liver Disease, NMR, nuclear magnetic resonance, NYHA, New York Heart Association, ROC, receiver operating characteristic, sTNF-R, soluble tumor necrosis factor–alpha receptor, TNF-α, tumor necrosis factor–alpha

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Drs Grünhage and Rezori contributed equally to this work.

 The authors disclose no financial conflicts of interest.

PII: S1542-3565(08)00673-3

doi:10.1016/j.cgh.2008.06.018

Clinical Gastroenterology and Hepatology
Volume 6, Issue 11 , Pages 1255-1262, November 2008